| 低剂量利妥昔单抗治疗难治性特发性膜性肾病的临床疗效分析 |
| |
| 引用本文： | 袁仲飞,刘先燕,何剑. 低剂量利妥昔单抗治疗难治性特发性膜性肾病的临床疗效分析[J]. 临床肾脏病杂志, 2021, 21(3): 215-219 |
| |
| 作者姓名： | 袁仲飞 刘先燕 何剑 |
| |
| 作者单位： | 重庆市开州区人民医院肾内科 405400;重庆市开州区人民医院电生理科 405400 |
| |
| 摘 要： | 目的 探讨低剂量利妥昔单抗(rituximab,RTX)治疗难治性特发性膜性肾病(idio-pathic membranous nephropathy,I N)的有效性及安全性.方法 回顾性收集2017年1月至2018年12月诊断的难治性IMN且抗磷脂酶A2受体(PLA2R)抗体阳性病例32例,接受低剂量RTX治疗方案...
|
| 关 键 词： | 利妥昔单抗 难治性特发性膜性肾病 有效性 安全性 |
Clinical analysis of low-dos erituximab in the treatment of refractory idiopathic membranous nephropathy |
| |
| Yuan Zhong-fei,Liu Xian-yan,He Jian. Clinical analysis of low-dos erituximab in the treatment of refractory idiopathic membranous nephropathy[J]. Journal Of Clinical Nephrology, 2021, 21(3): 215-219 |
| |
| Authors: | Yuan Zhong-fei Liu Xian-yan He Jian |
| |
| Affiliation: | (Department of Nephrology,Kaizhou District People's Hospital,Chongqing 405400,China;Department of Electrophysiology,Kaizhou District People's Hospital,Chongqing 405400,China) |
| |
| Abstract: | Objective To explore the efficacy and safety of low-dose rituximab(RTX)for refractory idiopathic membranous nephropathy(IMN).Methods From January 2017 to December 2018,32 cases of refractory IMN with positive anti-PLA2R antibody were collected.They received low-dose RTX treatment and were followed up for 1 year.Results The overall effective rate of low-dose RTX treatment for refractory IMN was 87.50%with a complete remission rate of 62.50%and a partial remission rate of 25.00%.After low-dose RTX treatment,CD19+B cell count,serum levels of total IgG and anti-PLA2R antibody declined markedly(P<0.05)and disease severity was closely correlated with anti-PLA2R antibody level.Adverse reactions of low-dose RTX treatment included agranulocytosis(n=2),hypotension during infusion(n=2)and pulmonary infection(n=1).Conclusion Low-dose rituximab is both effective and safe for refractory IMN. |
| |
| Keywords: | Rituximab Idiopathic membranous nephropathy Efficacy Safety |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
